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Macrolide antibiotics have anti-inflammatory and immunomodulatory properties in addition to
antibacterial activity. Until recently, only a small number of studies evaluating macrolides in
patients with non-cystic fibrosis (CF) bronchiectasis had been published. These were open-
label, uncontrolled, short-duration studies that included small numbers of patients. However,
these studies suggested that macrolides can reduce exacerbation frequency, reduce sputum
volume, and improve lung function in patients with non-CF bronchiectasis.
Three recently published randomised, double-blind, placebo-controlled studies showed that
macrolides (azithromycin or erythromycin) taken for between 6 and 12 months led to signifi-
cant reductions in exacerbation rate and reduced the decline in lung function. In all studies,
macrolides were generally well tolerated.
The advantages of macrolide maintenance therapy need to be balanced against the risks,
which include emergence of bacterial resistance, cardiotoxicity and ototoxicity. In addition,
a key need is the consistent definition of endpoints for studies in non-CF bronchiectasis, partic-
ularly the definition of exacerbation, to allow systematic data analysis. Existing studies on the
use of low-dose macrolides in non-CF bronchiectasis are encouraging, but further studies are
needed to define the optimal agent, dose, duration for treatment, and the patients likely to
benefit and long-term safety.
ª 2014 Elsevier Ltd. All rights reserved.)1480 364656; fax: þ44 (0)1480 364330.
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Bronchiectasis describes the pathological condition of
abnormally dilated airways [1]. Cystic fibrosis (CF) is one of
the leading inherited causes of bronchiectasis but there are
numerous other causes, including a post-infectious aeti-
ology (e.g. after pneumonia, pertussis, or Mycobacterium
infection), connective tissue disease, allergic broncho-
pulmonary aspergillosis, immunodeficiency, autoimmune
conditions, congenital ciliary defects or foreign body aspi-
ration [1e3]. In 26e53% of patients, bronchiectasis is idio-
pathic and has no known cause [1e3].
Bronchiectasis is increasing in prevalence in developing
countries and in some indigenous groups in affluent
countries [4e6]. With the increased life expectancy of the
global population, there is also greater risk of chronic
illness, including bronchiectasis, worldwide. Bronchiec-
tasis is commonly reported in developed countries, with
prevalence increasing with age [1]. The term ‘non-CF
bronchiectasis’ has been used to describe the group of
patients with bronchiectasis caused by conditions other
than CF [7].
The pathophysiology of bronchiectasis involves irre-
versible dilation and damage to the bronchial walls (con-
ducting airways) as a consequence of repeated infection
and subsequent inflammation. Mucociliary clearance is
impaired, so the airways are vulnerable to repeated colo-
nisation by pathogens [7]. Chronic infection promotes
further neutrophilic inflammation, leading to a vicious
cycle of infection and inflammation in the permanently
damaged airways. Patients present with persistent cough,
chronic daily sputum production and recurrent chest in-
fections [1]. Estimates suggest that the airways of almost
all patients with bronchiectasis are chronically infected
with pathogenic bacteria, even among those who are clin-
ically stable [8]. The most common infecting pathogens are
Haemophilus influenzae (47e55%) and Pseudomonasaeruginosa (12e26%) [1]. Bacterial load correlates with
inflammatory response, with greater numbers of neutro-
phils, and higher concentrations of neutrophil degradation
products and inflammatory markers [1,9].
Recent studies using pyrosequencing have demonstrated
a much greater diversity than was previously appreciated,
including many anaerobic species. The significance of these
is yet to be determined [8,10,11].
The aims of management of non-CF bronchiectasis in
adults are to identify and treat any underlying causes in
order to prevent disease progression; to maintain and
improve pulmonary function; to reduce exacerbation fre-
quency and severity; and to improve health-related quality
of life (HRQoL) by reducing symptoms and exacerbations
[7]. Management strategies include airway clearance
techniques, inhaled hyperosmolar agents, mucolytics,
inhaled corticosteroids, short- and long-term antibiotics
(either oral or nebulised) and surgery: though the evidence
base for most of these is poor [1,7]. Patient education is
also a key component of non-CF bronchiectasis manage-
ment and should focus on interventions that improve
quality of life (QoL) and reduce exacerbation frequency
along with the implementation of action plans to improve
the recognition and treatment of acute exacerbations [7].
The treatment of non-CF bronchiectasis has generally
consisted of treatments with proven efficacy in CF or other
diseases (e.g. chronic obstructive pulmonary disease
[COPD]), but this is by no means a sound strategy, as evi-
denced by the study of recombinant human deoxyribonu-
clease [12]. This treatment for CF was not only ineffective
in patients with idiopathic bronchiectasis, but potentially
harmful [12] and should not be used in this patient popu-
lation [7].
The British Thoracic Society guidelines on the manage-
ment of non-CF bronchiectasis highlight the current evi-
dence gaps, which limit recommendations for chronic
management strategies [7]. Bronchiectasis may not respond
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eases. Bronchodilators or inhaled corticosteroids may be
used in severe disease cases or when there is evidence of
reversibility [1,7]. Long-term antibiotic therapy may
improve symptoms and lung function by reducing the bac-
terial load for patients with bronchiectasis. Some classes of
antibiotics, particularly macrolides, tetracyclines and
quinolones, have immunomodulatory effects at concen-
trations lower than those required to kill the infecting or
colonising bacteria. Therefore, use of low-dose antibiotics
from these classes may modulate the persistent airway
inflammation that helps to perpetuate bacterial colonisa-
tion in the airways of patients with bronchiectasis [7].
Studies on the long-term use of antibiotics in non-CF
bronchiectasis have focused on macrolide antibiotics
[13e23]. Few of these studies have been randomised
controlled trials (RCTs) [13,18,20e23], most included fewer
than 50 patients [16e19,21,23], and were of relatively short
duration (3 months) [15,18,21,23]. The aims of this review
are to discuss the findings from recently reported RCTs of
macrolide treatment for non-CF bronchiectasis, and the im-
plications for clinical practice and future clinical trial design.
Review
Macrolides in chronic airways diseases
Macrolide antibiotics contain a macrocytic lactone ring
attached to a number of sugar moieties. They are classified
according to the number of lactone rings into 14-, 15- and
16-member ring macrolides. Their mechanism of action is
reversible binding to the 50 s subunit of prokaryocyte ri-
bosomes, blocking ribosomal translation and, ultimately,
bacterial replication [24]. Macrolides are bacteriostatic for
Staphylococci, Streptococci and Haemophilus. They are not
bactericidal against P. aeruginosa but inhibit biofilm for-
mation and toxin production [25].
The 14- and 15-member ring macrolides group include
erythromycin, clarithromycin, roxithromycin and
azithromycin [26]. These macrolides can down-regulate
inflammation and enhance or reduce activation of the im-
mune system in a time- and dose-dependent manner
[26]. Their actions include inhibiting the synthesis of
proinflammatory agents by bacteria, eosinophils, neutro-
phils and epithelial cells, and stimulating the phagocytic
activity of alveolar macrophages. They have also demon-
strated a number of immunomodulatory activities in vivo
and in vitro, including a reduction in T-cell numbers and T-
cell migration to the airway epithelium, inhibition of
neutrophil activation and mobilisation, acceleration of
neutrophil apoptosis, and a decrease in the production of
reactive oxygen species (Fig. 1) [26].
In addition to the immunomodulatory properties of
macrolides, there is a sound scientific rationale for studying
these agents in non-CF bronchiectasis, based on their
beneficial clinical effects including controlling exacerba-
tions in patients with CF [28], COPD [29] and diffuse pan-
bronchiolitis [26,30]. The small number of reports
published before 2012 had limitations [14e19,21,23].
However, these studies and case series showed reductions
in pulmonary exacerbations [14,16,17,19] and sputumvolumes [14e16,21,23], and improvements in lung function
[14,17,21]. One retrospective study found that older age
and male gender were independent predictors of response
to macrolide treatment [15]. The study of longest duration
was a prospective, open-label pilot study in which 21 pa-
tients were treated for 12 months with low-dose erythro-
mycin [19]. Compared with the preceding year, patients
taking erythromycin had half the median annual number of
infective exacerbations and annual days of antibiotic use.
Two of these studies investigated the potential mecha-
nisms of action in non-CF bronchiectasis [21,23]. Yalc¸in
et al. found that treatment with clarithromycin 15 mg/kg/
day for 3 months in children with non-CF bronchiectasis
significantly reduced levels of interleukin (IL)-8 in bron-
choalveolar lavage (BAL) fluid (p Z 0.006), but had no ef-
fect on levels of IL-10 or tumour necrosis factor-a [23]. The
concentration of bacterial isolates in BAL fluid did not
change in this study, suggesting that changes in neutrophil
and IL-8 levels resulted from an anti-inflammatory effect of
the clarithromycin [23].
In contrast to these findings, Tsang et al. found no
impact of erythromycin 500 mg twice daily for 8 weeks on
sputum levels of IL-1a, IL-8, tumour necrosis factor-a or
leukotriene-B4 in adult patients with non-CF bronchiectasis
[21]. It is not clear why there was no evidence of anti-
inflammatory effect in this study, whereas there was in
the study with clarithromycin in children, but it may have
been because the study was too small (n Z 21) or of too
short a duration (8 weeks) to detect a significant effect, or
that changes in levels of inflammatory markers are more
easily detected in BAL fluid compared to sputum. Even
without evidence of a clear anti-inflammatory effect, the
clinical benefits seen with macrolides in these short-term
studies suggested that these agents may have disease-
modifying effects in non-CF bronchiectasis, and led to
investigation in larger randomised trials.Clinical trial data
Data from three randomised, double-blind, placebo-
controlled trials have shown significant reductions in pul-
monary exacerbations in non-CF bronchiectasis patients
treated with long-term, low-dose macrolide therapy
[13,20,22].
The EMBRACE study
The Effectiveness of Macrolides in patients with Bronchi-
ectasis using Azithromycin to Control Exacerbations
(EMBRACE) study enrolled patients who had experienced at
least one respiratory exacerbation requiring antibiotics in
the previous year [22]. Patients (nZ 141) were randomised
to treatment with azithromycin 500 mg or placebo three
times a week. The study had three co-primary endpoints:
(1) the rate of event-based exacerbations at the end of the
6-month treatment period (defined as an increase in or new
onset of more than one pulmonary symptom - sputum vol-
ume, sputum purulence, or dyspnoea - requiring antibiotic
treatment); (2) change in forced expiratory volume in 1 s
(FEV1) before bronchodilation; and (3) change in St.
George’s Respiratory Questionnaire (SGRQ) total score at
the end of treatment.
Figure 1 Anti-inflammatory and immunomodulatory actions: underlying mechanisms [26].
Adapted and reprinted from [27]. Copyright ª 2011 Karger Publishers, Basel, Switzerland. GM-CSF, granulocyte-macrophage
colony-stimulating factor; IL, interleukin; MPO, myeloperoxidase; TNF-a, tumour necrosis factor-a.
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reduced the rate of exacerbations requiring antibiotic
treatment by almost two-thirds (p < 0.0001) during the 6-
month treatment period. Azithromycin also increased the
median time until 25% of patients had a first exacerbation
(p < 0.0001) and the median time to first exacerbation
during the overall 12-month study period (p < 0.0001)
(Fig. 2(a)). The effect on exacerbations persisted over the 6
months after treatment withdrawal. Based on the reported
percentage of patients with at least one event-based
exacerbation, it can be estimated that the number
needed to treat (NNT) with azithromycin to prevent
one patient having an exacerbation in 12 months is five
(Table 1).
Azithromycin did not significantly affect the rate of
symptom-based (patient-reported) exacerbations. These
exacerbations were defined as an increase in, or new onset
of, more than one pulmonary symptom (sputum volume,
sputum purulence, or dyspnoea) reported on diary cards,
and the mean of the three symptom scores for the daily
diary card increasing by at least one point on 2 consecutive
days, compared with the same calculation in the previous
week. It is not clear why there was a difference in exac-
erbation rates using the two definitions in this study [22],but it is possible that a higher rate of patient-reported
exacerbations may have been identified if the definition
included cough, which is the predominant symptom of
bronchiectasis.
The EMBRACE study did not meet the other two co-
primary endpoints: azithromycin had no statistically sig-
nificant effect on FEV1 or HRQoL as assessed by the SGRQ
total score [22]. After 6 months, symptoms were signifi-
cantly improved when assessing the SGRQ responses. This
improvement was no longer significant after 12 months of
azithromycin treatment [22], but this finding is consistent
with the effect of azithromycin in reducing the exacerba-
tion rate, because the symptom score is one of the SGRQ
components associated with exacerbation rate [31].
The BAT study
The Bronchiectasis and long-term Azithromycin Treatment
(BAT) study enrolled patients who had confirmed bronchi-
ectasis and had experienced at least three lower respira-
tory tract infections, and had at least one sputum culture
yielding at least one bacterial respiratory pathogen, in the
preceding year [13]. Patients (n Z 83) in this double-blind
study were randomised to receive azithromycin 250 mg/day
or placebo for 12 months. The primary endpoint of the
Macrolide therapy for non-CF bronchiectasis 1401study was the number of infectious exacerbations over the
12-month treatment period. Secondary endpoints included
lung infection, sputum bacteriology, inflammatory markers,
adverse effects, symptom scores, and QoL.
Azithromycin treatment significantly reduced the num-
ber of exacerbations compared with placebo, with a me-
dian of 0 versus 2 during treatment (p < 0.001). The number
of patients with at least one exacerbation during the study
was 80% in the placebo group and 46.5% in the azithromycin
group, corresponding to an absolute risk reduction of 34%
(Fig. 2(b)), or a NNT of three to prevent one patient having
an exacerbation in 12 months.
Azithromycin also significantly attenuated changes in
FEV1 and forced vital capacity (pZ 0.047 and pZ 0.020 vs.
placebo, respectively). There was no change in C-reactive
protein during azithromycin therapy. In contrast to
EMBRACE, azithromycin treatment was associated with
significant improvements in the SGRQ score compared with
placebo, and azithromycin recipients also had significantly
fewer symptoms than those receiving placebo (pZ 0.047).
There was evidence that antibacterial resistance
developed during the study, with 88% of pathogens tested
becoming macrolide resistant in sputum samples from the
azithromycin group compared with 26% in the placebo
group (p < 0.001) [13].
The BLESS study
At least two separate pulmonary exacerbations during the
previous 12 months and daily sputum production were
required for entry into this randomised, double-blind
Bronchiectasis and Low-dose Erythromycin Study (BLESS)
[20]. One hundred and seventeen patients received oral
erythromycin ethylsuccinate 400 mg twice daily (equivalent
to 250 mg of base erythromycin) or placebo for 12 months.
The primary endpoint was the number of protocol-defined
pulmonary exacerbations. Secondary endpoints were the
rate of all pulmonary events, change in the proportion of
commensal oropharyngeal streptococci resistant to mac-
rolides, symptoms, QoL, inflammatory markers, lung func-
tion, sputum bacteriology, and exercise capacity.
The number of protocol-defined pulmonary exacerba-
tions was 76 and 114 in the erythromycin and placebo
groups, respectively, corresponding to a mean of 1.29 and
1.97 per patient per year; incidence rate ratio 0.57
(p Z 0.003) (Fig. 2(c)). The number of patients with no
exacerbations was 20 in the erythromycin group and 16 in
the placebo group, resulting in an estimated NNT of 16 over
a 12-month period. Like azithromycin in BAT, erythromycin
significantly prevented the decline in FEV1 during the study
period. In contrast, erythromycin had no significant effect
on cough or QoL scores. Levels of inflammatory biomarkers
[20], C-reactive protein, and exercise tolerance were also
unchanged in erythromycin recipients. There was no dif-
ference between the two treatment groups with respect to
emergence of new sputum pathogens, but the proportion of
macrolide-resistant commensal oropharyngeal streptococci
increased significantly in erythromycin, but not placebo,
recipients [20].
Adverse events
Gastrointestinal side effects are the most common
complaint in patients treated with macrolides, although inrandomised trials of long-term, low-dose macrolide treat-
ment in chronic pulmonary diseases, these side effects
have been mild to moderate and rarely warranted treat-
ment discontinuation [13]. Gastrointestinal adverse events
were the most commonly reported adverse events in the
EMBRACE and BAT trials and occurred more frequently with
azithromycin than placebo (27e40% vs. 5e13% of patients)
[13,22].Key issues and controversies
The data from the EMBRACE, BAT and BLESS studies are
consistent with results from studies in adults and children
with CF and adults with COPD in showing that low-dose
macrolide maintenance therapy reduces the incidence of
exacerbations over 3 [32], 6 [33e35], or 12 [29] months of
treatment (Table 2). In the EMBRACE study, azithromycin
had no effect on lung function or QoL, whereas azi-
thromycin has improved both these parameters in some
[32,33], but not all, studies in patients with CF. In addition
to investigating the number of exacerbations during mac-
rolide therapy, the BAT study also investigated QoL and
found this to be significantly improved in patients receiving
azithromycin compared with those receiving placebo over 1
year of therapy [13]. However, this may have been a result
of the longer treatment duration in BAT compared with
EMBRACE (12 vs. 6 months, respectively).
While the optimal duration of treatment has not clearly
been established, the KaplaneMeier curves for remaining
exacerbation-free from the EMBRACE trial continued to
diverge beyond 3 months of treatment (Fig. 2(a)) [22]. This
was also the case in the BLESS trial, where the difference
between groups in the cumulative incidence of exacerba-
tions continued to increase up to 1 year [20]. In BAT, dif-
ferences between treatment groups in the proportion of
patients who were free of exacerbations were greatest at
3e6 months, but this difference was maintained over 1 year
of therapy [13]. Considering that the mechanisms of mac-
rolides probably include immunomodulatory activity [27],
and the duration of treatment in the RCTs of CF (3e6
months) [32e34], it is reasonable to assume that treatment
duration should be at least 3 months. Data from clinical
practice indicate that, in patients with CF, the beneficial
effects of azithromycin on lung function are limited to the
first 12 months of treatment [32,36,37]. Coupled with the
need to balance benefit with risk of macrolide resistance,
these data suggest that the optimal duration in non-CF
bronchiectasis is likely to be between 3 and 12 months.
Continuous treatment for longer than this requires clarifi-
cation in longer-term studies.
One of the key issues in the use of macrolides for pa-
tients with non-CF bronchiectasis is who to treat. In the
EMBRACE study, Wong et al. recommend that patients
should only receive azithromycin if they have experienced
at least one exacerbation in the previous year [22]. How-
ever, in an accompanying editorial, Wilson and Wells note
that they are ‘uneasy’ about this recommendation because
it may apply to almost all patients with clinically overt
bronchiectasis [38]. They note that non-CF bronchiectasis
generally shows one of two patterns of natural history: a
progressive course with frequent exacerbations despite
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Table 1 Comparison between Phase III clinical trials.
EMBRACE [22] BLESS [20] BAT [13]
Placebo Azithromycin Placebo Erythromycin Placebo Azithromycin
Patient, n 70 71 58 59 40 43
Male/female, n 20/50 23/48 25/33 21/38 12/28 18/25
Age, years 59.0 60.9 63.5 61.1 64.6 59.9
Study duration 6 months 12 months 12 months
FEV1 % predicted
at baseline
67.3 67.1 70.1 66.9 82.7 77.7
Change in FEV1
from baseline, L
0.04 0 4.0 1.6 0.10a 1.03a
SGRQ at baseline,
total score
36.6 31.9 38.1 36.7 40.2 40.6
Change in SGRQ total
score from baseline
1.92 5.17 1.3 3.9 4.12 12.18
Exacerbation rate in
12 months prior
to trial
3.93 3.34 NRb NRb 4.0 5.0
Total no. exacerbations
over 12 months
178c 109c 114 76 78 39
Annual exacerbation
rate, patient/year
2.73c 1.58c 1.97 1.27 1.95 0.91
Patients with at least
one exacerbation,
n (%)
58 (82.9) 44 (62.0) 42 (72.4) 39 (66.1) 32 (80.0) 20 (46.5)
NNT to prevent one
patient experiencing
an exacerbation over
12 monthsd
5 16 3
Data is mean unless otherwise stated.
a Data change per visit (every 3 months), F1,78.8 Z 4.085, p Z 0.047.
b BLESS study did not present exacerbation rate, but did present the number of patients with five or more exacerbations in the year
preceding the trial (n Z 20 and 22 for placebo and erythromycin respectively).
c EMBRACE was a 6-month study but presented annualised data for exacerbations.
d Calculated as 1/absolute risk reduction (proportion with event [placebo] e proportion with event [intervention]). Values presented
are the published NNT for BAT and estimates by the authors for EMBRACE and BLESS, based on the percentage of patients with exac-
erbation events. BAT, Bronchiectasis and long-term Azithromycin Treatment study; BLESS, Bronchiectasis and Low-dose Erythromycin
Study; EMBRACE, Effectiveness of Macrolides in patients with Bronchiectasis using Azithromycin to Control Exacerbations study; FEV1,
forced expiratory volume in 1 s; NNT, number needed to treat; NR, not recorded; SGRQ, St. George’s Respiratory Questionnaire.
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despite early major irreversible airway damage. Pulmonary
function testing poorly discriminates between these two
patterns of longitudinal disease progression, and therefore
it is difficult to identify prospectively those patients at high
risk of exacerbation [38]. Similarly, more data are required
to determine if benefits are consistent across bronchiec-
tasis phenotypes. For example, should patients with COPD-
versus non-COPD associated bronchiectasis receiveFigure 2 A Proportion of patients free from event-based exace
confidence intervals. Crosses indicate censoring. Reprinted from [22
of patients free from exacerbations in the BAT trial [13].
Reprinted from [13]. Copyright ª 2013 American Medical Associat
defined pulmonary exacerbations in the BLESS trial [20]. Each po
bation. Individual participants could account for more than one eve
of pulmonary exacerbations per year. Reprinted from [20]. Copyri
PDPE, protocol-defined pulmonary exacerbations.different treatment strategies? In patients with COPD, long-
term maintenance treatment with azithromycin benefited
patients in almost all subgroups based on demographics and
disease history, except for smokers [29]. Azithromycin had
the greatest benefit in elderly COPD patients (>65 years),
but was less effective in those with recent exacerbations
requiring hospitalisation or recent use of steroids, and
those taking inhaled corticosteroids, all factors indicative
of a high risk of recurrent exacerbations [29]. In childrenrbations in the EMBRACE trial [22]. Shaded areas indicate 95%
], Copyright 2012, with permission from Elsevier. 2B Proportion
ion. All rights reserved. 2C Cumulative incidence of protocol-
int represents a separate protocol-defined pulmonary exacer-
nt each; pZ 0.003 for the comparison with placebo for the rate
ght ª 2013 American Medical Association. All rights reserved.
Table 2 Randomised controlled trials of azithromycin maintenance therapy in patients with CF or COPD.
Reference Patients Azithromycin dose Duration of
treatment
Primary
endpoint
Key findings
CF
Wolter et al., 2002 [32] Adults (n Z 60) 250 mg/day 3 months FEV1 Improved lung function,
reduced exacerbations,
improved QoL
Saiman et al., 2003 [33] Children (n Z 185) 250 or 500 mg
3 times/wk
168 days FEV1 Improved lung function,
reduced exacerbations
Saiman et al., 2005 [34] Children (n Z 185) 250 or 500 mg
3 times/wk
168 days Exacerbations Reduced risk regardless
of change in FEV1. All
subgroups benefited
Saiman et al., 2010 [35] Children (n Z 260) 250 or 500 mg
3 times/wk
168 days FEV1 No FEV1 improvement
but reduced exacerbations
COPD
Albert et al., 2011 [29] Adults (n Z 1577) 250 mg/day 1 year Time to
exacerbation
Reduced exacerbations
CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; QoL, quality of life; wk, week.
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erbations with azithromycin in patients with or without P.
aeruginosa infection at baseline [33,35], and in all sub-
groups of P. aeruginosa-infected children, regardless of
whether or not they achieved an improvement in lung
function [34]. In fact, the reduction in the risk of exacer-
bation was greater in patients with lower FEV1 at baseline,
long-term users of recombinant human deoxyribonuclease,
and those on long-term inhaled tobramycin at baseline [34].
Similar data are needed from larger trials with pre-
specified subgroups of patients with non-CF bronchiectasis
to identify patients who may achieve the greatest benefit
from maintenance macrolide therapy. Limited data were
obtained from the BLESS trial, which suggested that pa-
tients with P. aeruginosa infection at baseline or 4 exac-
erbations in the year prior to the trial demonstrated
significant responses to erythromycin therapy [20]. Given
the reservations about applying long-term macrolide ther-
apy using the broad EMBRACE definition of exacerbation, it
has been suggested that non-CF bronchiectasis patients
who have more than two exacerbations per year may be the
most appropriate group for whom to consider long-term
treatment with macrolides [39].
Combined data from the EMBRACE, BAT and BLESS
studies provide good RCT evidence for the use of macrolide
maintenance therapy in adults with non-CF bronchiectasis
(Table 1) [13,20,22]. Azithromycin was the agent used in
two studies and erythromycin has been studied once.
However, in the absence of any direct comparative data,
there is insufficient evidence on which to base a conclusion
about which macrolide regimen has the optimal risk-benefit
profile in patients with non-CF bronchiectasis.
The frequency of exacerbations has been widely used as
an endpoint in non-CF bronchiectasis studies, including its
use as a primary endpoint in the large clinical trials, butdefinitions vary (Supplementary Table S1). This measure is
highly relevant to patients and healthcare providers. Pa-
tients with non-CF bronchiectasis have exacerbations at the
rate of 1.5e6.5 per patient per year [7,12], and these events
are associated with an increased risk of admission and re-
admission to hospital, as well as high healthcare costs
[40,41]. Moreover, the frequency of hospitalised exacerba-
tions is a determinant of accelerated lung function decline in
adults and children [42,43], and recurrent exacerbations are
a powerful predictor of poor HRQoL [44]. The three recent
studies used different definitions for exacerbation. The
EMBRACE study [22] defined exacerbation using the
Anthonisen criteria for an exacerbation in COPD, a definition
that includes changes in sputum volume and purulence, and
shortness of breath, but not cough, the predominant symp-
tom of bronchiectasis. In the BAT study, exacerbations were
defined as an increase in respiratory symptoms requiring
antibiotic treatment [13]. Finally, the BLESS study [20] also
used a definition adapted from Anthonisen: patients
requiring antibiotic administration for a sustained (>24-h)
increase in sputum volume; or purulence accompanied by
new deteriorations in at least two different symptoms
(sputum volume, sputum purulence, cough, dyspnoea, chest
pain, or haemoptysis). However, in this study, patients were
advised to contact a trial physician who would determine
whether antibiotic therapy was needed in the event of an
exacerbation. This aspect of the trial design could introduce
bias. EMBRACE avoided this by advising the patient’s general
practitioner or physician to avoidmacrolide antibiotics at the
start of the trial, but otherwise had no input into treatment
for exacerbations [22].
Other appropriate endpoints for RCTs in bronchiectasis
need to be defined. While there are some validated end-
points (e.g. Leicester Cough Questionnaire [45]) and the
SGRQ has been validated in bronchiectasis, there remains a
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chiectasis [1]. In contrast to previous data in other pulmo-
nary indications, the EMBRACE study showed no change in
FEV1 and the EMBRACE and BLESS studies showed no change
in SGRQ duringmacrolide therapy [20,22]. These data should
be consideredwith care as the SGRQwas developed to assess
QoL in patients with COPD [46], but has been validated for
use in bronchiectasis [31]. An alternative QoL measure has
been developed specifically to assess the effect of bron-
chiectasis (QoL-B), but this has yet to be fully validated [47].
While this may indicate that these endpoints are less
reflective of clinical improvement in non-CF bronchiectasis
than in other pulmonary conditions, significant attenuation
in the decline of lung function were seen in both BAT and
BLESS [13,20]. These findings were surprising as an earlier
trial investigating response to short-term courses of antibi-
otics in patients with bronchiectasis found that FEV1 values
do not change in response to treatment (unlike in treatment
for CF) [48], suggesting that FEV1 is not a good clinical
endpoint to use. Improvements in QoL were documented in
BAT [13], further complicating the decision about the
appropriateness of the different endpoints.
As described earlier, unanswered questions remain as to
the optimal dosage, duration, or periodicity of macrolide
regimens in non-CF bronchiectasis. While current data show
that treatment iswell tolerated innon-CFbronchiectasis, CF,
and COPD, there are potential safety concerns associated
with the long-term use of macrolides, including cardiac side
effects, that have been reported [24]. Arrhythmic events are
extremely rare and are unlikely to be identified in clinical
trials, and there were no adverse cardiac events in EMBRACE
or the study by Albert et al. in patients with COPD [22,29].
One erythromycin recipient in the BLESS study was with-
drawn as a result of suspected corrected Q-T interval pro-
longation, but further analysis showed that this patient had
been enrolled despite a correctedQ-T interval of 480ms, and
no further prolongation occurred during erythromycin ther-
apy [20]. Post-marketing data suggest a risk of an additional
47 cardiovascular deaths per 1 million with short (5-day)
courses of azithromycin, with the risk increasing in patients
with cardiovascular risk factors [49]. This underlines the
need to carefully consider the use of macrolide therapy, in
those with cardiovascular risk factors, and for ongoing
assessment of cardiac safety during clinical use. The study in
patients with COPD excluded patients with QT prolongation
at baseline, and it may be prudent to use similar exclusion
criteria in future studies in non-CF bronchiectasis and when
commencing treatment [29].
Reversible hearing loss has been associated with high-
dose macrolide therapy and the incidence of this side ef-
fect with long-term low-dose macrolide treatment has not
been well characterised [13]. Auditory side effects have
been reported with long-term azithromycin treatment in
COPD patients [29] but have not been studied properly in
bronchiectasis. While data from CF studies may provide
some information as to the tolerability profile of macro-
lides, both auditory and cardiovascular adverse events may
be more relevant in a non-CF bronchiectasis population,
which tends to be older than those with CF. An editorial
accompanying the BAT and BLESS publications suggested
that sputum culture, an electrocardiogram, and clinical
assessment of hearing and liver function should beundertaken prior to initiation of macrolide therapy, and at
regular intervals during treatment [39].
Development of pathogen resistance is a major concern
with the use of macrolides, and this may apply to bacteria
that are specific targets of macrolide therapy or commensal
organisms. Azithromycin and clarithromycin are the main-
stay of treatment for non-tuberculosis mycobacteria (NTM),
which are commonly found in bronchiectasis patients [24].
Recent data indicate that azithromycin impairs autophagic
and phagosomal degradation of macrophages, thereby
compromising host defences against Mycobacterium infec-
tion [50].This could explain why adult patients with CF on
long-term azithromycin therapy are at increased risk of
developing NTM infection, particularly infection with
multidrug-resistant species of Mycobacterium abscessus
[50]. It is not clear if long-term azithromycin predisposes to
NTM infection. In a small study of 14 cases an association
between azithromycin use and NTM was demonstrated, but
two larger multicentre case control studies in patients with
CF did not show the same finding [50e52]. Longer surveil-
lance studies with more cases are required to determine if
this is a clinical problem. RCTs in CF patients who were
treated for up to 168 days with azithromycin did not show
any increased risk of developing NTM infection [32,33,35],
suggesting that treatment duration may be a key factor in
limiting the potential for NTM development in non-CF
bronchiectasis. Nevertheless, it will be important to
monitor microbiology during future trials to limit the risk of
NTM infections during macrolide therapy, which may
severely limit future NTM treatment options.
Also of concern is the potential for development of
resistance in commensal organisms, especially oropharyn-
geal streptococci that can then be transmitted within the
community. Even a short course of azithromycin is associ-
ated with a substantial increase in resistance among pa-
tients’ oropharyngeal streptococci [8]. One study found a
statistically significant 53.4% increase in macrolide-
resistant streptococci after 3 days of azithromycin treat-
ment in healthy volunteers [53]. The RCTs in patients
with CF or COPD showed an increased rate of macrolide
resistance among S. aureus strains after 5e12 months of
treatment with azithromycin [29,35]. Data in CF patients
shows that long-term azithromycin treatment reduces car-
riage of S. aureus but increases the rate of macrolide
resistance among S. aureus strains [28,37,54]. However,
resistant strains of S. aureus do not appear to be trans-
mitted to household contacts [54]. Macrolide resistance
testing was not routinely carried out in the EMBRACE study
[22]. However, two patients (4%) in the azithromycin arm
developed macrolide-resistant S. pneumoniae at 6 months
[22]. The design of both BAT and BLESS included routine
assessment of sputum samples and secondary endpoints
included microbiological evaluation with susceptibility
testing (BAT) and changes in the proportion of commensal
oropharyngeal streptococci resistant to macrolides. The
results of these trials suggested that no new pathogens
emerged during macrolide therapy [13,20]. However, the
proportion of macrolide-resistant commensal oropharyn-
geal streptococci increased significantly during erythro-
mycin therapy and macrolide resistance of known
respiratory pathogens was significantly increased in azi-
thromycin recipients [13,20]. The clinical significance of
1406 C.S. Haworth et al.this is unclear. While these data provide additional infor-
mation that was not available from the EMBRACE study,
there are a number of concerns that remain to be
addressed, including the possibility that macrolide use
might increase resistance to other antibiotics and the ef-
fect of macrolides on antibiotic resistance among other
pathogens [39]. Some concerns about increasing community
and patient resistance have been raised, but there is little
existing evidence [55].
Implications for future research
Current data on the use of low-dose macrolides in non-CF
bronchiectasis are encouraging. Data in CF patients suggest
that macrolide treatment may cease to provide clinical
benefit after 12 months [36,37], but it remains to be
determined whether this is the case for non-CF
bronchiectasis.
Additional clinical trials with large patient numbers and
longer follow-up periods are also needed to assess safety.
Studies should be conducted in patients of different age
groups, including elderly and paediatric patients. One such
study, the Bronchiectasis Interventional Study (BIS), is
evaluating the effect of 12e24 months of treatment with
azithromycin in indigenous children with non-CF bronchi-
ectasis in Alaska, Australia, and New Zealand [56].
Careful attention will need to be paid to the potential
for cardio- and ototoxicity with long-term macrolide ther-
apy. Until further data are available on the safety of low-
dose macrolide therapy in this patient group, studies should
have stringent selection criteria that include baseline
electrocardiogram assessment and exclusion of anyone with
cardiovascular disease or significant cardiovascular risk
factors.
Routine testing of macrolide resistance should be
included in future clinical trials, including macrolide sus-
ceptibility of oropharyngeal flora. Macrolide resistance in
respiratory bacteria colonising the nasopharynx is a sec-
ondary endpoint in the BIS trial of long-term, low-dose
azithromycin in paediatric patients described earlier [56].
Ideally, there should be consistent definitions for end-
points in non-CF bronchiectasis studies, so that the data
can be systematically analysed to support evidence-based
recommendations. To this end, validated patient-reported
outcomes and QoL assessment tools are needed in
bronchiectasis.
Researchers should also continue to investigate the
mechanism of action of low-dose macrolide therapy in
bronchiectasis, particularly the role of anti-inflammatory
and immunomodulatory effects. A study currently under-
way into the effects of long-term, low-dose azithromycin
on airway oxidative stress markers in exhaled breath
condensate of adults with non-CF bronchiectasis, may help
to clarify these mechanisms [NCT01463371;
clinicaltrials.gov].
Conclusions
Macrolide antibiotics possess additional anti-inflammatory
and immunomodulatory properties in addition to their
antimicrobial function. There is now an evidence base fromthree RCTs for the long-term use of low-dose macrolides in
non-CF bronchiectasis. Owing to concerns about drug
resistance, it seems prudent to limit macrolide treatment
to patients with functionally severe disease. Those with
milder disease should only receive long-term macrolide
treatment in cases of major morbidity and/or evidence of
disease progression despite standard treatment [38]. Pri-
orities for future research include identifying the optimal
regimen and duration of macrolide treatment to maximise
clinical efficacy and minimise emergence of resistance,
direct comparisons of different macrolides in non-CF
bronchiectasis, and development and validation of
bronchiectasis-specific endpoints. The anti-inflammatory
and immunomodulatory properties of macrolides without
the antimicrobial activity and inherent risk of pathogen
resistance should also be explored.
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